Pipeline of Mesothelin-Targeted Immunotherapies

This competitive intelligence report about Mesothelin-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting mesothelin. This report will be prepared on demand within one working day upon order placement. The report lists mesothelin-targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of mesothelin-targeted immunotherapies by drug modality. The report will be provided in pdf format and sent by e-mail to the customer.

As an example of this category of on demand reports please see our free sample report of “Pipeline of 5T4-Targeted Immunotherapies”.

Mesothelin, a 40 kD glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein, is overexpressed in many cancers, potentially involved in adhesion and metastasis. The well-known interacting partner of mesothelin is CA125/MUC16, a member of the mucin family of glycoproteins which is expressed in ovarian cancer and malignant mesothelioma Given the limited expression of mesothelin in normal tissues and overexpression in several tumor cells, mesothelin presents a desirable target for tumor-specific therapy.

Mesothelin expression has been identified in approximately 30% of cancers, including mesothelioma, ovarian, pancreatic, gastric, and non–small cell lung tumors, uterine malignancies as well as cholangiocarcinoma. In high grade ovarian cancer, mesothelin is overexpressed in 75% to 80% of patients. Normal expression of mesothelin is on mesothelial cells lining pleura, peritoneum, and pericardium. Low expression may be found on some other tissues, but anti-mesothelin antibodies or antibody-toxin conjugates have not shown much toxicity.

Although several first generation drug modalities used for targeting mesothelin eventually have failed in clinical studies, such as immunotoxins, thorium-targeted therapies, antibody-drug conjugates, chimeric antigen receptor T cells, natural killer cells as well as T-cell engaging antibodies, improved next generation versions of such drug modalities have been developed and are applied to novel immunotherapy candidates for mesothelin-expressing cancers.